Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT03280563
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 37
- Registration Number
- NCT03219476
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 82
- Registration Number
- NCT03211572
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 377
- Registration Number
- NCT03161353
- Locations
- 🇫🇷
Hospital Georges Pompidou, Paris, France
🇮🇹Istituto Europeo di Oncologia, Milan, Italy
🇵🇹Hospital Senhora da Oliveira, Guimarães, Portugal
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2018-10-31
- Target Recruit Count
- 300
- Registration Number
- NCT03137368
- Locations
- 🇨🇳
CancerIHCAMS, Beijing, Beijing, China
Treatment With Tamoxifen in Cryptococcal Meningitis
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2019-12-02
- Target Recruit Count
- 50
- Registration Number
- NCT03112031
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
🇻🇳Cho Ray Hospital, Ho Chi Minh City, Vietnam
🇻🇳Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03058939
- Locations
- 🇳🇬
Lagos State University College of Medicine, Ikeja, Lagos State, Nigeria
The Effect of Tamoxifen on Clinical Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle.
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT03060304
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 144
- Registration Number
- NCT03011684
- Locations
- 🇺🇸
University of California at San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.